Fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment
Summary
USPTO granted Patent US12590081B2 to Jiangsu Hengrui Pharmaceuticals Co., Ltd. for fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment. The patent covers 21 claims for compounds, preparation methods, and pharmaceutical compositions containing the derivatives.
What changed
USPTO granted Patent US12590081B2 (effective March 31, 2026) to Jiangsu Hengrui Pharmaceuticals Co., Ltd. for fused imidazole derivatives functioning as GLP-1 receptor agonists for treating diabetes. The patent, filed April 2, 2021 (Application No. 17907458), contains 21 claims covering the compounds, methods of preparation, and pharmaceutical compositions containing the derivatives.
Pharmaceutical companies and R&D teams developing GLP-1 receptor agonists or diabetes treatments should review this patent for freedom-to-operate purposes. Competitors should assess whether their own compound development or manufacturing processes may infringe upon the claims related to these fused imidazole derivatives and their therapeutic applications.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Fused imidazole derivatives, preparation method and medicinal use thereof
Grant US12590081B2 Kind: B2 Mar 31, 2026
Assignee
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Inventors
Fanglong Yang, Qian Yang, Feng He, Weikang Tao
Abstract
The present disclosure relates to fused imidazole derivatives, preparation methods and medical use thereof. Specifically, the present disclosure relates to a fused imidazole derivative represented by the general formula (I), the preparation method thereof, and the pharmaceutical composition containing the same, as well as the use as a therapeutic agent, especially as GLP-1 receptor agonists, and the use thereof in the preparation of medicaments for the treatment and/or prevention of diabetes. The substituents of general formula (I) are the same as defined in the specification.
CPC Classifications
C07D 401/14 C07D 405/14 C07D 471/04 A61K 31/444 A61K 31/4439 A61P 3/10
Filing Date
2021-04-02
Application No.
17907458
Claims
21
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.